MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [ 18 F] AV45 and FDG PET Imaging
Brain and Behavior · 2025
DOI: 10.1002/brb3.70572 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2025. Verfasst von Parsa Saberian und 13 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Hauptthemen laut MEDLINE: Alzheimer Disease, MicroRNAs, Amyloidosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Purpose
Alzheimer's disease (AD) is a neurodegenerative disease primarily manifesting with cognitive decline. This study aimed to investigate the alterations in microRNAs in patients across AD continuum as potential biomarkers.
Method
Data were extracted from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, including microRNA levels in the serum and cerebrospinal fluid (CSF) of patients across AD continuum. We analyzed the associations between microRNA levels and previously known AD biomarkers, such as amyloid beta (Aβ) accumulations in the brain and glucose reuptake values using positron emission tomography ([ 18 F]AV45 and FDG PET, respectively).
Findings
The study found a significant positive correlation between CSF levels of miR‐210‐3p and Aβ accumulations in the brain (B = 4.69). Conversely, miR‐223‐3p levels were significantly lower in APOE‐ε4 carriers. Significant negative correlations were also observed between glucose reuptake and several miRNAs in the AD group. Specifically, plasma levels of let‐7g‐5p, mir‐423‐5p, and mir‐660‐5p were negatively associated with glucose reuptake in the brain.
Conclusion
Elevated levels of miR‐210‐3p correlate with Aβ accumulation, supporting previous findings of increased levels of certain microRNAs in patients with MCI and AD. Our findings highlight the potential of microRNAs as biomarkers of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, Faculty of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
- Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran.
- Faculty of Science, University of Tabriz, Tabriz, Iran.
- Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Cell and Molecular Biology and Microbiology, Faculty of Biological Sciences and Technology, University of Isfahan, Isfahan, Iran.
- Institute for Cognitive Science Studies, Pardis, Iran.
ORCID-Profile: Afra Darvishi, Mohamad Hatami Nejad, Mahsa Mayeli, Shayan Shakeri
Zitieren
APA
Saberian, P., Darvishi, A., Khezragha, D., Forouzandegan, M., Farhadieh, M. E., Taghizadeh Khorshidi, S., Hatami Nejad, M., Sedighi, S., Barati, R., Safavi, S. A. R., Sadeghi, M., Gulisashvili, D., Mayeli, M., & Shakeri, S. (2025). MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [ 18 F] AV45 and FDG PET Imaging. Brain and Behavior. https://doi.org/10.1002/brb3.70572
Vancouver
Saberian P, Darvishi A, Khezragha D, Forouzandegan M, Farhadieh ME, Taghizadeh Khorshidi S, et al. MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [ 18 F] AV45 and FDG PET Imaging. Brain and Behavior. 2025. doi:10.1002/brb3.70572
BibTeX
@article{Saberian2025,
author = {Saberian, Parsa and Darvishi, Afra and Khezragha, Delnia and Forouzandegan, Moojan and Farhadieh, Mohammad-Erfan and Taghizadeh Khorshidi, Shaghayegh and Hatami Nejad, Mohamad and Sedighi, Sara and Barati, Reza and Safavi, Seyed Ahmad Reza and Sadeghi, Mohammad and Gulisashvili, David and Mayeli, Mahsa and Shakeri, Shayan},
title = {MicroRNA Signatures Predict Brain Amyloidosis and Neurodegeneration in Alzheimer’s Disease: Insights from [ 18 F] AV45 and FDG PET Imaging},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70572}
}
EUVIMED